These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 33951089)
1. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants. Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P; PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089 [TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR; J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337 [TBL] [Abstract][Full Text] [Related]
3. Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy. Goldberg RN; Kania AT; Michienzi SM; Patel M; Badowski ME J Int Assoc Provid AIDS Care; 2021; 20():2325958221996860. PubMed ID: 33626965 [TBL] [Abstract][Full Text] [Related]
4. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor. Verburgh ML; Wit FWNM; Boyd A; Verboeket SO; Reiss P; van der Valk M Open Forum Infect Dis; 2022 Jul; 9(7):ofac291. PubMed ID: 35873291 [TBL] [Abstract][Full Text] [Related]
5. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Kerchberger AM; Sheth AN; Angert CD; Mehta CC; Summers NA; Ofotokun I; Gustafson D; Weiser SD; Sharma A; Adimora AA; French AL; Augenbraun M; Cocohoba J; Kassaye S; Bolivar H; Govindarajulu U; Konkle-Parker D; Golub ET; Lahiri CD Clin Infect Dis; 2020 Jul; 71(3):593-600. PubMed ID: 31504324 [TBL] [Abstract][Full Text] [Related]
6. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts. Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K; Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392 [TBL] [Abstract][Full Text] [Related]
7. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T; AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493 [TBL] [Abstract][Full Text] [Related]
8. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV. Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678 [No Abstract] [Full Text] [Related]
9. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163 [TBL] [Abstract][Full Text] [Related]
10. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy. Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049 [TBL] [Abstract][Full Text] [Related]
11. Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism. Savinelli S; Newman E; Mallon PWG Curr HIV/AIDS Rep; 2024 Dec; 21(6):293-308. PubMed ID: 39207722 [TBL] [Abstract][Full Text] [Related]
12. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women. Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420 [TBL] [Abstract][Full Text] [Related]
13. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844 [TBL] [Abstract][Full Text] [Related]
14. Association between switching to integrase strand transfer inhibitors and incident diabetes in people with HIV. Hwang YJ; Lesko CR; Brown TT; Alexander GC; Zalla LC; Keruly JC; Snow LN; Pytell JD; Falade-Nwulia O; Jones JL; Moore RD; Fojo AT AIDS; 2024 Sep; 38(11):1696-1702. PubMed ID: 38864578 [TBL] [Abstract][Full Text] [Related]
15. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus. Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155 [TBL] [Abstract][Full Text] [Related]
16. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV. Han WM; Kerr SJ; Avihingsanon A; Boettiger DC J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517 [TBL] [Abstract][Full Text] [Related]
17. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004 [TBL] [Abstract][Full Text] [Related]
18. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims. Tse J; Prajapati G; Zhao X; Near AM; Kumar PN Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288 [TBL] [Abstract][Full Text] [Related]
19. No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gain. Verburgh ML; Wit FWNM; Boyd A; Reiss P; Van der Valk M; AIDS; 2023 Oct; 37(12):1843-1850. PubMed ID: 37433218 [TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of weight gain following switch from efavirenz- to integrase inhibitor-containing regimens. Wu K; Koethe J; Hulgan T; Brown T; Bares SH; Tassiopoulos K; Lake JE; Leonard M; Samuels DC; Erlandson K; Haas DW Pharmacogenet Genomics; 2024 Feb; 34(2):25-32. PubMed ID: 37910437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]